The estimated Net Worth of Michael M Tarnow is at least 3.18 百万$ dollars as of 18 May 2021. Mr. Tarnow owns over 8,229 units of Xenon Pharmaceuticals Inc stock worth over 3,012,458$ and over the last 10 years he sold XENE stock worth over 0$. In addition, he makes 169,615$ as Independent Chairman of the Board at Xenon Pharmaceuticals Inc.
Sign up
Mr. Tarnow XENE stock SEC Form 4 insiders trading
Michael has made over 13 trades of the Xenon Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 8,229 units of XENE stock worth 30,612$ on 18 May 2021.
The largest trade he's ever made was exercising 14,403 units of Xenon Pharmaceuticals Inc stock on 12 December 2016 worth over 46,234$. On average, Michael trades about 3,279 units every 101 days since 2014. As of 18 May 2021 he still owns at least 77,942 units of Xenon Pharmaceuticals Inc stock.
You can see the complete history of Mr. Tarnow stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Tarnow biography
Michael M. Tarnow J.D. serves as Independent Chairman of the Board of the Company. Mr. Tarnow has been an advisor to and member of the boards of directors of private and public healthcare and biotechnology companies in the U.S., Canada and Europe, including Axcan Pharma, Creative Biomolecules, Inc., Caprion Pharmaceuticals Inc. and MediGene AG. He served as chair of EntreMed, Inc. (now CASI Pharmaceuticals, Inc.) a publicly-traded biotechnology company, from February 2003 to February 2009, and served as Executive Chair of EntreMed from February 2009 to January 2012. Mr. Tarnow holds a B.B.A. in Business Administration from Wayne State University and a J.D. from the University of Illinois, College of Law. Our Board believes that Mr. Tarnow is qualified to serve on our Board because of his senior management experience in the pharmaceutical industry and his knowledge and perspective of the Corporation.
What is the salary of Michael Tarnow?
As the Independent Chairman of the Board of Xenon Pharmaceuticals Inc, the total compensation of Michael Tarnow at Xenon Pharmaceuticals Inc is 169,615$. There are 8 executives at Xenon Pharmaceuticals Inc getting paid more, with Simon Pimstone having the highest compensation of 2,612,720$.
How old is Michael Tarnow?
Michael Tarnow is 74, he's been the Independent Chairman of the Board of Xenon Pharmaceuticals Inc since . There are no older and 22 younger executives at Xenon Pharmaceuticals Inc.
What's Michael Tarnow's mailing address?
Michael's mailing address filed with the SEC is 200 - 3650 GILMORE WAY, , BURNABY, A1, V5G 4W8.
Insiders trading at Xenon Pharmaceuticals Inc
Over the last 10 years, insiders at Xenon Pharmaceuticals Inc have traded over 12,977,011$ worth of Xenon Pharmaceuticals Inc stock and bought 724,015 units worth 2,649,316$ . The most active insiders traders include Patrick Machado、Partners L P/Ilbiotechnolog...、Justin D. Gover. On average, Xenon Pharmaceuticals Inc executives and independent directors trade stock every 31 days with the average trade being worth of 818,878$. The most recent stock trade was executed by Elizabeth A. Garofalo on 8 March 2024, trading 3,500 units of XENE stock currently worth 64,960$.
What does Xenon Pharmaceuticals Inc do?
xenon® (nasdaq: xene) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as extreme genetics. our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. we apply our expertise to predict which phenotypes are caused by single-gene defects. by identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.
What does Xenon Pharmaceuticals Inc's logo look like?
Complete history of Mr. Tarnow stock trades at Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc executives and stock owners
Xenon Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Simon Pimstone,
Chief Executive Officer, Director -
Ian Mortimer,
President, Chief Financial Officer, Corporate Secretary -
Ernesto Aycardi-Fonseca,
Chief Medical Officer -
Dr. Simon N. Pimstone FRCPC, M.B. ChB., M.D., Ph.D.,
Exec. Chairman -
Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA,
Pres, CEO & Director -
Robin Sherrington,
Executive Vice President - Strategy & Innovation -
James Empfield,
Senior Vice President - Drug Discovery -
Dr. Christopher John Kenney M.D.,
Chief Medical Officer -
Michael Tarnow,
Independent Chairman of the Board -
Dawn Svoronos,
Independent Director -
Gary Patou,
Independent Director -
Frank Holler,
Independent Director -
Michael Hayden,
Independent Director -
Steven Gannon,
Independent Director -
Clarissa Desjardins,
Independent Director -
Mohammad Azab,
Independent Director -
Shelley McCloskey,
Senior Vice President - Human Resources -
Dr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D.,
Chief Commercial Officer -
Dr. Kenneth Sommerville,
Interim Chief Medical Officer -
Dr. Christopher E. Von Seggern M.B.A., M.P.H., Ph.D., M.P.H. M.B.A,
Chief Commercial Officer -
Sheila M. Grant M.B.A., M.Sc., MBA,
Sr. VP of R&D Operations -
Dr. James R. Empfield,
Exec. VP of Drug Discovery -
Dr. Robin P. Sherrington,
Exec. VP of Strategy & Innovation -
Shelley McCloskey B.A.,
Sr. VP of HR -
Jodi Regts M.B.A., B.A., MBA,
VP of Corp. Affairs & Investor Relations -
Sherry Aulin,
Chief Financial Officer -
Charles J. Cohen,
VP, Biology -
Raymond Winquist,
Head, Translational Research -
Partners L P/Ilbiotechnolog...,
-
Richard H Scheller,
Director -
Christopher John Kenney,
Chief Medical Officer -
Sherry Aulin,
Chief Financial Officer -
Seggern Christopher Von,
Chief Commercial Officer -
Elizabeth A. Garofalo,
-
Patrick Machado,
-
Y. Paul Goldberg,
VP, Clinical Development -
Associates, Llp Mx,
10% owner -
Karen G. Corraini,
Gen. Counsel & Corp. Secretary -
Johnston L Evans,
Director -
Evan A. Stein,
Director -
Gary Bridger,
EVP, Research & Development -
Gillian Cannon,
-
Justin D. Gover,